Viva Biotech's portfolio companies have recently announced significant progress in their respective research and development programs, as well as securing substantial funding to further advance their pipelines. These achievements span various therapeutic areas, including dermatology, ophthalmology, metabolic diseases, oncology, and genetic disorders.
TechnoDerma Medicines' TDM-180935 Shows Promise in Atopic Dermatitis
TechnoDerma Medicines, a clinical-stage biopharmaceutical company, announced the completion of a Phase 2a clinical trial (NCT06363461) of its topical TDM-180935 ointment for the treatment of Atopic Dermatitis (AD). The results demonstrated that the treatment was well-tolerated and exhibited strong efficacy. Notably, the study showed minimal systemic exposure, suggesting the potential for application across large body surface areas often affected by AD. These findings support the continued development of TDM-180935 for Atopic Dermatitis, a chronic inflammatory skin condition affecting millions worldwide.
VivaVision's VVN461 Demonstrates Efficacy in Ocular Diseases
VivaVision Biotech, focused on developing treatments for ocular diseases, reported positive results for its VVN461, a first-in-class non-steroidal dual JAK1/TYK2 immunomodulator. In a Phase II clinical trial in China, VVN461 achieved clinical endpoints for non-infectious anterior uveitis, demonstrating excellent anti-inflammatory effects. Both dosage groups achieved statistical significance for non-inferiority compared to the positive control, 1% prednisolone acetate eye drops, in both primary and secondary efficacy endpoints. Additionally, VivaVision announced positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201 for post-operative inflammation following cataract surgery, where it showed statistical and clinical improvements across primary and many secondary endpoints compared to vehicle.
Antag Therapeutics Secures Funding for Obesity Treatment
Antag Therapeutics, a biopharmaceutical company focused on developing novel therapies for obesity and cardiometabolic diseases, announced the closing of an €80 million Series A financing round. The funding will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR). This funding will also fuel the expansion of Antag's pipeline of monthly injectable therapies. AT-7687 represents a promising approach to obesity treatment by targeting the GIP receptor, a key regulator of insulin secretion and energy homeostasis.
Other Notable Developments
- Arthrosi Therapeutics has enrolled more than 50% of patients in its pivotal Phase 3 REDUCE 2 trial evaluating AR882 for the reduction of serum urate in gout patients.
- Full Circles Therapeutics published a groundbreaking study in Nature Biotechnology on non-viral immune cell engineering using circular single-stranded DNA.
- Apeiron Therapeutics enrolled the first patient in its Phase 1a/b study of PRMT5 inhibitor GTA182 for MTAP-deleted solid tumors.
- AceLink Therapeutics' AL01211 was granted Breakthrough Therapy designation in China for Fabry Disease.
